Clinical Data
| Patients . | Age (yr) . | Sex . | Diagnosis . | Splenomegaly . | WBC (×109/L) . | Hb (g/L) . | PLT (×109/L) . |
|---|---|---|---|---|---|---|---|
| t1 | 58 | M | ET | − | 69.9 | 13.9 | 840 |
| t2 | 39 | F | ET | − | 10.4 | 13.7 | 743 |
| t3 | 64 | M | ET | − | 13.5 | 14.9 | 769 |
| t4 | 68 | M | ET | − | 12 | 12.7 | 785 |
| t5 | 86 | F | ET | + | 6.2 | 13.4 | 950 |
| t6 | 45 | F | ET | − | 7.5 | 12.8 | 850 |
| t7 | 43 | F | ET | − | 5.8 | 14.5 | 700 |
| t8 | 50 | M | ET | − | 4.1 | 14.2 | 850 |
| t9 | 39 | F | ET | − | 4.5 | 12.6 | 1035 |
| t10 | 82 | F | ET | − | 15 | 13 | 1200 |
| t11 | 45 | M | ET | − | 5 | 14 | 900 |
| t12 | 35 | F | ET | − | 8.1 | 12.2 | 860 |
| t13 | 34 | M | ET | − | 9.9 | 14.5 | 1350 |
| t14 | 58 | F | ET | − | 8.4 | 14.7 | 910 |
| t15 | 53 | F | ET | − | 12.4 | 12.1 | 1200 |
| t16 | 67 | F | ET | − | 9.7 | 12.8 | 730 |
| t17 | 11 | F | ET | − | 7.3 | 12.6 | 1340 |
| t18 | 46 | F | ET | − | 4.2 | 11.7 | 1270 |
| t19 | 59 | M | ET | − | 13.3 | 15 | 806 |
| t20 | 35 | F | ET | + | 10 | 10.7 | 663 |
| t21 | 65 | M | ET | − | 9.6 | 16.3 | 927 |
| m1 | 60 | F | PMF | ++ | 19.7 | 8.6 | 231 |
| m2 | 62 | M | PMF | ++ | 51.3 | 10.7 | 89 |
| m3 | 60 | M | PMF | ++ | 6.8 | 12 | 68 |
| m4 | 82 | M | PMF | ++ | 19 | 9.8 | 96 |
| m5 | 50 | M | PMF | ++ | 14.4 | 14 | 290 |
| m6 | 45 | M | PMF | ++ | 4.3 | 7 | 45 |
| m7 | 49 | M | PMF | + | 2.5 | 8.4 | 98 |
| m8 | 52 | F | PMF | + | 11 | 13.5 | 800 |
| m9 | 69 | F | PMF | + | 5.1 | 8.5 | 319 |
| m10 | 63 | M | PMF | ++ | 4.4 | 11 | 231 |
| m11 | 67 | F | PMF | + | 27 | 12 | 178 |
| m12 | 54 | M | PMF | ++ | 23 | 10.5 | 221 |
| m13 | 70 | M | PMF | ++ | 80 | 11.3 | 196 |
| m14 | 49 | M | PMF | ++ | 8.8 | 8 | 727 |
| Patients . | Age (yr) . | Sex . | Diagnosis . | Splenomegaly . | WBC (×109/L) . | Hb (g/L) . | PLT (×109/L) . |
|---|---|---|---|---|---|---|---|
| t1 | 58 | M | ET | − | 69.9 | 13.9 | 840 |
| t2 | 39 | F | ET | − | 10.4 | 13.7 | 743 |
| t3 | 64 | M | ET | − | 13.5 | 14.9 | 769 |
| t4 | 68 | M | ET | − | 12 | 12.7 | 785 |
| t5 | 86 | F | ET | + | 6.2 | 13.4 | 950 |
| t6 | 45 | F | ET | − | 7.5 | 12.8 | 850 |
| t7 | 43 | F | ET | − | 5.8 | 14.5 | 700 |
| t8 | 50 | M | ET | − | 4.1 | 14.2 | 850 |
| t9 | 39 | F | ET | − | 4.5 | 12.6 | 1035 |
| t10 | 82 | F | ET | − | 15 | 13 | 1200 |
| t11 | 45 | M | ET | − | 5 | 14 | 900 |
| t12 | 35 | F | ET | − | 8.1 | 12.2 | 860 |
| t13 | 34 | M | ET | − | 9.9 | 14.5 | 1350 |
| t14 | 58 | F | ET | − | 8.4 | 14.7 | 910 |
| t15 | 53 | F | ET | − | 12.4 | 12.1 | 1200 |
| t16 | 67 | F | ET | − | 9.7 | 12.8 | 730 |
| t17 | 11 | F | ET | − | 7.3 | 12.6 | 1340 |
| t18 | 46 | F | ET | − | 4.2 | 11.7 | 1270 |
| t19 | 59 | M | ET | − | 13.3 | 15 | 806 |
| t20 | 35 | F | ET | + | 10 | 10.7 | 663 |
| t21 | 65 | M | ET | − | 9.6 | 16.3 | 927 |
| m1 | 60 | F | PMF | ++ | 19.7 | 8.6 | 231 |
| m2 | 62 | M | PMF | ++ | 51.3 | 10.7 | 89 |
| m3 | 60 | M | PMF | ++ | 6.8 | 12 | 68 |
| m4 | 82 | M | PMF | ++ | 19 | 9.8 | 96 |
| m5 | 50 | M | PMF | ++ | 14.4 | 14 | 290 |
| m6 | 45 | M | PMF | ++ | 4.3 | 7 | 45 |
| m7 | 49 | M | PMF | + | 2.5 | 8.4 | 98 |
| m8 | 52 | F | PMF | + | 11 | 13.5 | 800 |
| m9 | 69 | F | PMF | + | 5.1 | 8.5 | 319 |
| m10 | 63 | M | PMF | ++ | 4.4 | 11 | 231 |
| m11 | 67 | F | PMF | + | 27 | 12 | 178 |
| m12 | 54 | M | PMF | ++ | 23 | 10.5 | 221 |
| m13 | 70 | M | PMF | ++ | 80 | 11.3 | 196 |
| m14 | 49 | M | PMF | ++ | 8.8 | 8 | 727 |
Clinical characteristics of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Splenomegaly is quoted − if absent, + or ++ according to the spleen size.
Abbreviations: F, female; M, male; WBC, white blood cells; Hb, hemoglobin; PLT, platelets.